Search

Your search keyword '"Perrin, Christophe"' showing total 675 results
Start Over Author "Perrin, Christophe"
675 results on '"Perrin, Christophe"'

1. Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study

Author

Duffaud, Florence, Blay, Jean-Yves, Le Cesne, Axel, Chevreau, Christine, Boudou-Rouquette, Pascaline, Kalbacher, Elsa, Penel, Nicolas, Perrin, Christophe, Laurence, Valérie, Bompas, Emmanuelle, Saada-Bouzid, Esma, Delcambre, Corinne, Bertucci, François, Cancel, Mathilde, Schiffler, Camille, Monard, Laure, Bouvier, Corinne, Vidal, Vincent, Gaspar, Nathalie, and Chabaud, Sylvie

Published
2023
Full Text
View/download PDF

2. Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Author

Jerusalem, Guy, Park, Yeon Hee, Yamashita, Toshinari, Hurvitz, Sara A, Modi, Shanu, Andre, Fabrice, Krop, Ian E, Farré, Xavier Gonzàlez, You, Benoit, Saura, Cristina, Kim, Sung-Bae, Osborne, Cynthia R, Murthy, Rashmi K, Gianni, Lorenzo, Takano, Toshimi, Liu, Yali, Cathcart, Jillian, Lee, Caleb, and Perrin, Christophe

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Breast Cancer, Prevention, Clinical Research, Neurosciences, Cancer, Clinical Trials and Supportive Activities, Humans, Female, Breast Neoplasms, Receptor, ErbB-2, Trastuzumab, Immunoconjugates, Camptothecin, Brain Neoplasms, Receptor, erbB-2, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

DESTINY-Breast01 (NCT03248492) evaluated trastuzumab deruxtecan (T-DXd; DS-8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC). We present a subgroup of 24 patients with a history of treated brain metastases (BM), a population with limited treatment options. In patients with BMs, the confirmed objective response rate (cORR) was 58.3% [95% confidence interval (CI), 36.6%-77.9%], and the median progression-free survival (mPFS) was 18.1 months (95% CI, 6.7-18.1 months). In patients without BMs (n = 160), cORR was 61.3% and mPFS was 16.4 months. Eight patients (47.1%) experienced a best overall intracranial response of partial response or complete response. Seven patients (41.2%) had a best percentage change in brain lesion diameter from baseline consistent with stable disease. Two patients (8.3%) with BMs and two (1.3%) without BMs experienced progression in the brain. The safety profile of T-DXd was consistent with previous studies. The durable clinical activity of T-DXd in this population warrants further investigation.SignificanceAdvances in treating HER2-positive metastatic breast cancer have greatly improved patient outcomes, but intracranial progression remains an important risk for which few therapeutic options are currently available. T-DXd demonstrated durable efficacy in patients with stable, treated BMs. This article is highlighted in the In This Issue feature, p. 2711.

Published
2022

3. Prone position versus usual care in hypoxemic COVID-19 patients in medical wards: a randomised controlled trial

Author

Nay, Mai-Anh, Hindre, Raphaël, Perrin, Christophe, Clément, Jérémy, Plantier, Laurent, Sève, Aymeric, Druelle, Sylvie, Morrier, Marine, Lainé, Jean-Baptiste, Colombain, Léa, Corvaisier, Grégory, Bizien, Nicolas, Pouget-Abadie, Xavier, Bigot, Adrien, Jamard, Simon, Nyamankolly, Elsa, Planquette, Benjamin, Fossat, Guillaume, and Boulain, Thierry

Published
2023
Full Text
View/download PDF

4. Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC

Author

Kubicek, Pierre, Cesne, Axel Le, Lervat, Cyril, Toulmonde, Maud, Chevreau, Christine, Duffaud, Florence, Le Nail, Louis-Romée, Morelle, Magali, Gaspar, Nathalie, Vérité, Cécile, Castex, Marie-Pierre, Penel, Nicolas, Saada, Esma, Causeret, Sylvain, Bertucci, François, Perrin, Christophe, Bompas, Emmanuelle, Orbach, Daniel, Laurence, Valérie, Piperno-Neumann, Sophie, Anract, Philippe, Rios, Maria, Gentet, Jean-Claude, Mascard, Éric, Pannier, Stéphanie, Blouin, Pascale, Carrère, Sébastien, Chaigneau, Loïc, Soibinet-Oudot, Pauline, Corradini, Nadège, Boudou-Rouquette, Pascaline, Ruzic, Jean-Christophe, Lebrun-Ly, Valérie, Dubray-Longeras, Pascale, Varatharajah, Sharmini, Lebbe, Céleste, Ropars, Mickaël, Kurtz, Jean-Emmanuel, Guillemet, Cécile, Lotz, Jean-Pierre, Berchoud, Juliane, Cherrier, Grégory, Ducimetière, Françoise, Chemin, Claire, Italiano, Antoine, Honoré, Charles, Desandes, Emmanuel, Blay, Jean-Yves, Gouin, François, and Marec-Bérard, Perrine

Published
2023
Full Text
View/download PDF

5. Consensus français sur les syndrome d’apnées et hypopnées centrales du sommeil (SAHCS) de l’adulte. Préambule : contexte et méthodologie utilisée

Author

Launois Rollinat, Sandrine, Barateau, Lucie, Bironneau, Vanessa, Barone-Rochette, Gilles, D’Ortho, Marie Pia, Jullian-Desayes, Ingrid, Gentina, Thibaut, Lequeux, Benoit, Lombard, Rémy, Mallet, Jean Pierre, Martin, Francis, Meslier, Nicole, Monaca, Christelle, Nowak, Stefan, Petiau, Christophe, Perrin, Christophe, Philippe, Carole, Portel, Laurent, Priou, Pascaline, Puel, Vincent, Redolfi, Stefania, Roche, Frédéric, Roubille, François, Tamisier, Renaud, Thoin, Fabrice, Trzepizur, Wojciech, Meurice, Jean Claude, Gagnadoux, Frédéric, and Jaffuel, Dany

Published
2024
Full Text
View/download PDF

10. Development of sensitive and robust multiplex digital PCR assays for the detection of ESR1 mutations in the plasma of metastatic breast cancer patients

Author

Corné, Julien, Quillien, Véronique, Callens, Céline, Portois, Pascal, Bidard, François-Clément, Jeannot, Emmanuelle, Godey, Florence, Le Du, Fanny, Robert, Lucie, Bourien, Héloïse, Brunot, Angélique, Crouzet, Laurence, Perrin, Christophe, Lefeuvre-Plesse, Claudia, Diéras, Véronique, and de la Motte Rouge, Thibault

Published
2023
Full Text
View/download PDF

11. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Author

Modi, Shanu, Saura, Cristina, Yamashita, Toshinari, Park, Yeon Hee, Kim, Sung-Bae, Tamura, Kenji, Andre, Fabrice, Iwata, Hiroji, Ito, Yoshinori, Tsurutani, Junji, Sohn, Joohyuk, Denduluri, Neelima, Perrin, Christophe, Aogi, Kenjiro, Tokunaga, Eriko, Im, Seock-Ah, Lee, Keun Seok, Hurvitz, Sara A, Cortes, Javier, Lee, Caleb, Chen, Shuquan, Zhang, Lin, Shahidi, Javad, Yver, Antoine, and Krop, Ian

Subjects
Cancer, Clinical Research, Breast Cancer, Clinical Trials and Supportive Activities, 6.2 Cellular and gene therapies, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Camptothecin, Consolidation Chemotherapy, Female, Humans, Immunoconjugates, Intention to Treat Analysis, Kaplan-Meier Estimate, Lung Diseases, Interstitial, Middle Aged, Progression-Free Survival, Receptor, ErbB-2, Trastuzumab, DESTINY-Breast01 Investigators, Receptor, erbB-2, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundTrastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation.MethodsIn this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2-positive metastatic breast cancer who had received previous treatment with trastuzumab emtansine. In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose. The primary end point was the objective response, according to independent central review. Key secondary end points were the disease-control rate, clinical-benefit rate, duration of response and progression-free survival, and safety.ResultsOverall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kilogram of body weight). In the intention-to-treat analysis, a response to therapy was reported in 112 patients (60.9%; 95% confidence interval [CI], 53.4 to 68.0). The median duration of follow-up was 11.1 months (range, 0.7 to 19.9). The median response duration was 14.8 months (95% CI, 13.8 to 16.9), and the median duration of progression-free survival was 16.4 months (95% CI, 12.7 to not reached). During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%). On independent adjudication, the trial drug was associated with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%).ConclusionsTrastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppression, interstitial lung disease was observed in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.).

Published
2020

15. Plasma‐based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer

Author

Corné, Julien, primary, Quillien, Véronique, additional, Godey, Florence, additional, Cherel, Mathilde, additional, Cochet, Agathe, additional, Le Du, Fanny, additional, Robert, Lucie, additional, Bourien, Héloïse, additional, Brunot, Angélique, additional, Crouzet, Laurence, additional, Perrin, Christophe, additional, Lefeuvre‐Plesse, Claudia, additional, Diéras, Véronique, additional, and De la Motte Rouge, Thibault, additional

Published
2024
Full Text
View/download PDF

16. Epithelioid Sarcoma

Author

Pedrono, Maud, Le Loarer, François, Ropars, Mickael, Williaume, Danièle, Corradini, Nadège, Perrin, Christophe, Chevreau, Christine, editor, and Italiano, Antoine, editor

Published
2020
Full Text
View/download PDF

17. Nail Telocytes: Identification, Potential Physiological Function, and Role in Pathology: A Reappraisal of the So-Called Onychofibroblasts/Onychodermis

Author

Perrin, Christophe

Abstract

Some authors have suggested that the fibroblasts of the nail mesenchyme (onychofibroblasts) can be distinguished from skin fibroblasts by their high expression of CD10. My 2015 study documented the presence of a relatively sparse CD34+/CD10+dendritic subpopulation in the dermis and hypodermis of the matrix. For some time now, my hypothesis has been that these interstitial dendritic mesenchymal cells of the matrix correspond to telocytes. Telocytes have been described as peculiar interstitial dendritic cells present in the mesenchymal tissue of numerous organs, including the skin, but their presence and characteristics in the nail unit have not been explored. This study was undertaken to more comprehensively investigate the existence and characteristics of nail telocytes. A series of 20 normal adult nail units were examined with a combination of morphological and immunohistochemical analyses. The matrix dermis contained a sparse subpopulation of CD34+/CD10+elongated telocytes with a higher density in the lunular region and, at this distal level, a change in their immunohistochemical profile, resulting in a progressive loss of CD34 expression. The matrix hypodermis showed CD34+/CD10+telocytes in their classical elongated aspect, which acquired, especially in the distal fibromyxoid area of the thumb, an oval to round morphology with multiple intracytoplasmic vacuoles. The characteristic dynamic immunophenotypic profile of the dermal telocytes with a progressive distal loss of the defining molecule CD34 was equally observed in the distal hypodermis. The nail bed dermis was thick with a dense fibrous connective tissue. A reticular network of CD34−/CD10+telocytes was present in the superficial dermis of the proximal nail bed. The mesenchymal cells of the deep part of the proximal nail bed dermis and the entire distal nail bed dermis were CD34−/CD10−. The adult nail mesenchyme is composed of 3 microanatomically distinct regions. Only the thumb has a distal hypodermis rich in mucinous material. The population of telocytes is relatively sparse compared with the fibroblastic population of the entire nail mesenchyme. The concept of onychodermis/onychofibroblasts is not valid. Nail telocytes have a dynamic immunohistochemical profile depending on whether they are located proximally or distally. The CD34+/CD10+profile correlates with the onychogenic epithelial region, while the CD34−/CD10+profile correlates with a spatial rearrangement of the nail epidermal bed.

Published
2024
Full Text
View/download PDF

20. Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort

Author

Frank, Sophie, Carton, Matthieu, Dubot, Coraline, Campone, Mario, Pistilli, Barbara, Dalenc, Florence, Mailliez, Audrey, Levy, Christelle, D’Hondt, Véronique, Debled, Marc, Vermeulin, Thomas, Coudert, Bruno, Perrin, Christophe, Gonçalves, Anthony, Uwer, Lionel, Ferrero, Jean-Marc, Eymard, Jean-Christophe, Petit, Thierry, Mouret-Reynier, Marie-Ange, Patsouris, Anne, Guesmia, Tahar, Bachelot, Thomas, Robain, Mathieu, and Cottu, Paul

Published
2020
Full Text
View/download PDF

28. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Author

Bouzid, Kamel, Campone, Mario, Coudert, Bruno, Nowecki, Zbigniew, Errihani, Hassan, Dalenc, Florence, Ferreira, Ana, Mano, Max, Ricci, Francesco, Kalofonos, Haralabos, Andreetta, Claudia, Montemurro, Filippo, Barrett, Sophie, Zhang, Qingyuan, Mavroudis, Dimitris, Matus, Juan, Beato, Carlos, Hu, Xichun, Gaafar, Rabab, Abdel Azeem, Hamdy, Perrin, Christophe, Ettl, Johannes, Lang, Istvan, Verma, Sunil, Li, Huiping, Brain, Etienne, Hoffmann, Oliver, Cariello, Anna, Tondini, Carlo, Altwegeiri, Taher, Loman, Niklas, Lux, Michael, Frassoldati, Antonio, Aziz, Zeba, Salas, Fernando, Streb, Joanna, Wronski, Andrzej, Menjón Beltrán, Salomón, Cicin, Irfan, Schmid, Peter, Laing, Robert, Tong, Zhongsheng, Boer, Katalin, Juhasz, Balazs, Gianni, Luca, Curigliano, Giuseppe, Juarez, Alejandro, Susnjar, Snezana, Matos, Erika, Uslu, Ruchan, Wildiers, Hans, Cruz, Marcelo, Bourgeois, Hugues, von Schumann, Raquel, Stemmer, Salomón, Vásquez, Flavia Morales, Dominguez, Adriana, Wojtukiewicz, Marek, Trifunovic, Jasna, Illarramendi, Jose Juan, Garcia, Laura, Peron, Yann Izarzugaza, Echarri, Maria Jose, Voitko, Natliia, Wheatley, Duncan, Waters, Simon, De Boer, Richard, Jerusalem, Guy, Cocquyt, Véronique, Barrios, Carlos, Panasci, Lawrence, Mattson, Johanna, Tanner, Minna, Gozy, Michel, Vasilopoulos, Georgios, Revesz, Janos, Latini, Luciano, Gridelli, Cesare, Lazaro, Jesus, Gonzalez, Antonio, Barnadas Molins, Agusti, Martinez, Eduardo, Alarcón, Jesús, Arance, Ana, Klint, Leif, Kovalyov, Oleksiy, Baird, Richard, Yeo, Belinda, McCarthy, Nicole, Greil, Richard, Wang, Shusen, Artignan, Xavier, Augereau, Paule, Juhasz-Boess, Ingolf, Ngan, Roger, Goldberg, Hadassah, Di Costanzo, Francesco, Ferraù, Francesco, Aleknavicius, Eduardas, Rashid, Kamran, Costa, Luís, Angel Garcia, Jose, de la Cruz, Luis Ruiz, López López, Rafael, Del Val, Olga, Ozyilkan, Ozgur, Azribi, Fathi, Verrill, Mark, Turner, Nicholas, Beith, Jane, Petzer, Andreas, Andrade, Jurandyr, Bernstein, Vanessa, Rayson, Daniel, Saad Eldin, Ibtessam, Achille, Mihaëla, Mueller, Volkmar, Gennari, Alessandra, Cascinu, Stefano, Ghosn, Marwan, El-Saghir, Nagi, Van den Bosch, Joan, Oosterkamp, Rianne, Kukulska, Monika, Pelaez, Ignacio, Hernandez, Carolina, del Mar Gordon, Maria, Dalmau, Elsa, Alonso, Jose Luis, Aksoy, Sercan, Coskun, Hasan Senol, Shparyk, Yaroslav, Varughese, Mohini, Panwar, Udaiveer, Barraclough, Lisa, Levitt, Nicola, Hicks, Jonathan, Rigg, Anna, Allen, Mark, Castillo, Cecila, Fein, Luis Enrique, Stuart-Harris, Robin, Singer, Christian, Stoeger, Herbert, Smiljanic, Sasha, Feng, Jifeng, Cedeño, Miguel, Berdah, Jean Francois, Orfeuvre, Hubert, Goncalves, Anthony, Grischke, Eva-Maria, Simon, Eike, Wagner, Steffen, Efremidou, Anna, Papazisis, Konstantinos, Evron, Ella, Inbar, Moshe, Baruch, Noa Ben, Geffen, David, Karminsky, Natalya, Ruggeri, Enzo Maria, Luigi, Cavanna, Grasso, Donatella, Juozaityte, Elona, Rafael Rodriguez Cid, Jeronimo, Roerdink, Henk, Siddiqi, Neelum, Passos Coelho, José Luís, Garre, Elisa Garcia, Garcia, Andres, Martínez Jañez, Noelia, Lopez Ceballos, Maria Helena, Mele, Mireia, García, María, Arcediano, Alberto, McAdam, Karen, Perren, Timothy, Taylor, Wendy, Humphreys, Alison, Vera, Raul, Kaen, Luis Alberto, Steger, Günther, Andel, Johannes, de Grève, Jacques, Huizing, Manon, Hegg, Roberto, Joy, Anil, Sehdev, Sandeep, Kütner, Riina, Ruohola, Johanna, Dohollou, Nadine, Grosjean, Jessica, Laplaige, Philippe, Largillier, Rémy, Martin, Philippe, Pottier, Virginie, Alexandre, Jerome, Christensen, Bernd, Zahm, Dirk-Michael, Khandan, Fariba, Lueck, Hans-Joachim, Fountzilas, Georgios, Fried, Georgeta, Giacobino, Alice, Bonetti, Andrea, Guerra, Yanin Chavarri, Van Warmerdam, Laurens, Van der Velden, Annette, Vrijaldenhoven, Suzan, de Jongh, Felix, Cavero, Milagros, Andres Conejero, Raquel, Murias, Adolfo, Saura, Salvador, Oltra, Amparo, Redondo, Andres, Ribelles, Nuria, Bachmeier, Kilian, Joffe, Johnathan, Chakraborti, Prabir, Beresford, Mark, Butt, Mohammad, Poole, Christopher, Yordi, Gassan, Woodward, Natasha, Amorim, Gilberto, Califaretti, Nadia, Fox, Susan, Robidoux, Andre, Li, NanLi, Li, Nenxiao, Jiang, Jun, Soria, Tannia, Padrik, Peeter, Saarni, Outi, Genet, Dominique, Catala, Stéphanie, Barletta, Hugues, Teixeira, Luis, Facchini, Thomas, Hesse, Tobias, Kühn, Thorsten, Ober, Angelika, Repp, Roland, Schroeder, Willibald, Pectasides, Dimitrios, Bodoky, Gyorgy, Kahan, Zsuzsanna, Jiveliouk, Irina, Rosengarten, Ora, Alabiso, Oscar, Perez, Mario, Van de Wouw, Yes, Smok-Kalwat, Jolanta, Damasceno, Margarida, Sousa, Gabriela, Abulkhair, Omalkhair, Antón Torres, Antonio, Martinez, Maria Purificación, Garcia Mata, Jesús, Jesús Florián Jerico, Marta Santisteban, Llombart, Antonio, Sanchez, Rosa, Torrego, Juan Carlos, Garate, Clara Olier, Rodriguez, Cesar, Llorente, Rosa, de Prado, Diego Soto, Cortés, Javier, Llorca, Cristina, Galán, Antonio, Viñas Villaro, Gemma, Narbe, Ulrik, Bjömeklett, Helena Granstam, Westwell, Sarah, Newby, Jackie, Jafri, Mariam, Rodríguez, Robinson, Alonso, Isabel, Bachelot, T., Ciruelos, E., Schneeweiss, A., Puglisi, F., Peretz-Yablonski, T., Bondarenko, I., Paluch-Shimon, S., Wardley, A., Merot, J.-L., du Toit, Y., Easton, V., Lindegger, N., and Miles, D.

Published
2019
Full Text
View/download PDF

38. Supplementary Data from Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Author

Jerusalem, Guy, primary, Park, Yeon Hee, primary, Yamashita, Toshinari, primary, Hurvitz, Sara A., primary, Modi, Shanu, primary, Andre, Fabrice, primary, Krop, Ian E., primary, Gonzàlez Farré, Xavier, primary, You, Benoit, primary, Saura, Cristina, primary, Kim, Sung-Bae, primary, Osborne, Cynthia R., primary, Murthy, Rashmi K., primary, Gianni, Lorenzo, primary, Takano, Toshimi, primary, Liu, Yali, primary, Cathcart, Jillian, primary, Lee, Caleb, primary, and Perrin, Christophe, primary

Published
2023
Full Text
View/download PDF

39. Data from Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Author

Jerusalem, Guy, primary, Park, Yeon Hee, primary, Yamashita, Toshinari, primary, Hurvitz, Sara A., primary, Modi, Shanu, primary, Andre, Fabrice, primary, Krop, Ian E., primary, Gonzàlez Farré, Xavier, primary, You, Benoit, primary, Saura, Cristina, primary, Kim, Sung-Bae, primary, Osborne, Cynthia R., primary, Murthy, Rashmi K., primary, Gianni, Lorenzo, primary, Takano, Toshimi, primary, Liu, Yali, primary, Cathcart, Jillian, primary, Lee, Caleb, primary, and Perrin, Christophe, primary

Published
2023
Full Text
View/download PDF

40. Prone-position versus usual care in hypoxemic COVID-19 patients in medical wards: a randomized controlled trial

Author

NAY, Mai-Anh, primary, HINDRE, Raphaël, additional, PERRIN, Christophe, additional, CLÉMENT, Jérémy, additional, PLANTIER, Laurent, additional, SÈVE, Aymeric, additional, DRUELLE, Sylvie, additional, MORRIER, Marine, additional, LAINÉ, Jean-Baptiste, additional, COLOMBAIN, Léa, additional, CORVAISIER, Grégory, additional, BIZIEN, Nicolas, additional, POUGET-ABADIE, Xavier, additional, BIGOT, Adrien, additional, JAMARD, Simon, additional, NYAMANKOLLY, Elsa, additional, PLANQUETTE, Benjamin, additional, FOSSAT, Guillaume, additional, and BOULAIN, Thierry, additional

Published
2023
Full Text
View/download PDF

41. Évolution à 6 mois de la qualité du sommeil dans le syndrome d’apnées centrales du sommeil (SACS) traitées par VAA : étude FACIL-VAA

Author

Tamisier, Renaud, primary, Philippe, Carole, additional, Prigent, Arnaud, additional, Charley-Monaca, Christelle, additional, D’Ortho, Marie-Pia, additional, Gentina, Thibaut, additional, Gagnadoux, Frédéric, additional, Launois, Claire, additional, Mallet, Jean-Pierre, additional, Didi, Toufik, additional, Guy, Tiphaine, additional, Goutorbe, Frédéric, additional, Perrin, Christophe, additional, Pontier-Marchandise, Sandrine, additional, Timsit, Jean-François, additional, Pepin, Jean-Louis, additional, and Meurice, Jean Claude, additional

Published
2023
Full Text
View/download PDF

46. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial

Author

Mir, Olivier, Brodowicz, Thomas, Italiano, Antoine, Wallet, Jennifer, Blay, Jean-Yves, Bertucci, François, Chevreau, Christine, Piperno-Neumann, Sophie, Bompas, Emmanuelle, Salas, Sébastien, Perrin, Christophe, Delcambre, Corinne, Liegl-Atzwanger, Bernadette, Toulmonde, Maud, Dumont, Sarah, Ray-Coquard, Isabelle, Clisant, Stéphanie, Taieb, Sophie, Guillemet, Cécile, Rios, Maria, Collard, Olivier, Bozec, Laurence, Cupissol, Didier, Saada-Bouzid, Esma, Lemaignan, Christine, Eisterer, Wolfgang, Isambert, Nicolas, Chaigneau, Loïc, Cesne, Axel Le, and Penel, Nicolas

Published
2016
Full Text
View/download PDF

49. Patterns of care and outcome of CIC ‐rearranged sarcoma patients: A nationwide study of the French sarcoma group

Author

Brahmi, Mehdi, primary, Gaspar, Nathalie, additional, Gantzer, Justine, additional, Toulmonde, Maud, additional, Boudou‐Rouquette, Pascaline, additional, Bompas, emmanuelle, additional, Firmin, Nelly, additional, Valentin, Thibaud, additional, Cancel, Mathilde, additional, Duffaud, Florence, additional, Bertucci, Francois, additional, Perrin, Christophe, additional, Dufresne, Armelle, additional, Marec‐Bérard, Perrine, additional, Jean‐Denis, Myriam, additional, Ray‐Coquard, Isabelle, additional, Le Loarer, Francois, additional, Pierron, Gaille, additional, Tirode, Franck, additional, Blay, Jean‐Yves, additional, and Watson, Sarah, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results